X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs ALEMBIC PHARMA - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA ALEMBIC PHARMA SUN PHARMA/
ALEMBIC PHARMA
 
P/E (TTM) x 31.9 16.5 193.2% View Chart
P/BV x 2.7 3.6 74.1% View Chart
Dividend Yield % 0.5 1.1 44.7%  

Financials

 SUN PHARMA   ALEMBIC PHARMA
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
ALEMBIC PHARMA
Mar-19
SUN PHARMA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs701664 105.5%   
Low Rs433412 105.0%   
Sales per share (Unadj.) Rs110.4208.7 52.9%  
Earnings per share (Unadj.) Rs11.031.0 35.4%  
Cash flow per share (Unadj.) Rs17.237.1 46.4%  
Dividends per share (Unadj.) Rs2.005.50 36.4%  
Dividend yield (eoy) %0.41.0 34.5%  
Book value per share (Unadj.) Rs158.8144.2 110.1%  
Shares outstanding (eoy) m2,399.26188.52 1,272.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.12.6 199.1%   
Avg P/E ratio x51.617.4 297.4%  
P/CF ratio (eoy) x32.914.5 226.9%  
Price / Book Value ratio x3.63.7 95.7%  
Dividend payout %18.217.7 102.7%   
Avg Mkt Cap Rs m1,360,021101,461 1,340.4%   
No. of employees `00017.8NA-   
Total wages/salary Rs m53,6717,467 718.8%   
Avg. sales/employee Rs Th14,890.9NM-  
Avg. wages/employee Rs Th3,017.1NM-  
Avg. net profit/employee Rs Th1,480.6NM-  
INCOME DATA
Net Sales Rs m264,89539,347 673.2%  
Other income Rs m8,38894 8,942.0%   
Total revenues Rs m273,28239,441 692.9%   
Gross profit Rs m56,0818,736 642.0%  
Depreciation Rs m14,9981,152 1,301.6%   
Interest Rs m5,176184 2,811.4%   
Profit before tax Rs m44,2957,493 591.1%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-93 0.0%   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,4521,568 539.2%   
Profit after tax Rs m26,3385,844 450.7%  
Gross profit margin %21.222.2 95.4%  
Effective tax rate %19.120.9 91.2%   
Net profit margin %9.914.9 66.9%  
BALANCE SHEET DATA
Current assets Rs m316,35919,577 1,615.9%   
Current liabilities Rs m198,64314,896 1,333.5%   
Net working cap to sales %44.411.9 373.5%  
Current ratio x1.61.3 121.2%  
Inventory Days Days9590 105.7%  
Debtors Days Days10845 237.4%  
Net fixed assets Rs m213,17827,097 786.7%   
Share capital Rs m2,399377 636.4%   
"Free" reserves Rs m378,60626,811 1,412.1%   
Net worth Rs m381,00627,188 1,401.4%   
Long term debt Rs m17,7214,993 354.9%   
Total assets Rs m643,02847,778 1,345.9%  
Interest coverage x9.641.7 22.9%   
Debt to equity ratio x00.2 25.3%  
Sales to assets ratio x0.40.8 50.0%   
Return on assets %4.912.6 38.8%  
Return on equity %6.921.5 32.2%  
Return on capital %10.023.6 42.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m40,81619,453 209.8%   
Fx outflow Rs m30,1436,065 497.0%   
Net fx Rs m10,67313,388 79.7%   
CASH FLOW
From Operations Rs m39,0728,120 481.2%  
From Investments Rs m-33,708-7,556 446.1%  
From Financial Activity Rs m-15,393590 -2,607.1%  
Net Cashflow Rs m-7,3591,153 -638.1%  

Share Holding

Indian Promoters % 63.7 74.1 86.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 2.9 176.9%  
FIIs % 23.0 9.1 252.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 13.9 59.7%  
Shareholders   133,026 49,328 269.7%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   ELDER PHARMA  FDC LTD.  SHASUN PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  

Compare SUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Yes Bank's Road Ahead(Podcast)

The stock markets witnessed selling pressure in the week gone by. Market participants remained cautious tracking tepid quarterly earnings amid weak cues.

Related Views on News

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jul 19, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS